Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity

被引：38

作者：

Carter, Gregory T. ^{[1
]}

Flanagan, Aaron M.

Earleywine, Mitchell ^{[2
]}

Abrams, Donald I. ^{[3
]}

Aggarwal, Sunil K. ^{[4
]}

Grinspoon, Lester ^{[5
,6
]}

机构：

[1] Providence Med Grp, Hospice Serv, Olympia, WA USA

[2] SUNY Albany, Dept Psychol, Albany, NY 12222 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] NYU, Rusk Inst Rehabil Med, New York, NY 10003 USA

[5] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA

[6] Massachusetts Mental Hlth Ctr, Boston, MA 02115 USA

来源：

AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE | 2011年 / 28卷 / 05期

关键词：

cannabis; medical marijuana; opioids; hospice; chronic pain; palliative medicine; CHRONIC NEUROPATHIC PAIN; UNITED-STATES; COMPARATIVE SAFETY; WASHINGTON-STATE; OVERDOSE DEATHS; CB1; RECEPTORS; SPINAL-CORD; MARIJUANA; ALCOHOL; TRENDS;

D O I：

10.1177/1049909111402318

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I (dangerous, without medical uses). Dronabinol, a Schedule III prescription drug, is 100% tetrahydrocannabinol (THC), the most psychoactive ingredient in cannabis. Cannabis contains 20% THC or less but has other therapeutic cannabinoids, all working together to produce therapeutic effects. As palliative medicine grows, so does the need to reclassify cannabis. This article provides an evidence-based overview and comparison of cannabis and opioids. Using this foundation, an argument is made for reclassifying cannabis in the context of improving palliative care and reducing opioid-related morbidity.

引用

页码：297 / 303

页数：7

共 103 条

[1] Vaporization as a smokeless cannabis delivery system: A pilot study [J].

Abrams, D. I. ;

Vizoso, H. P. ;

Shade, S. B. ;

Jay, C. ;

Kelly, M. E. ;

Benowitz, N. L. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (05) :572-578

[2] Cannabis in painful HIV-associated sensory neuropathy - A randomized placebo-controlled trial [J].

Abrams, D. I. ;

Jay, C. A. ;

Shade, S. B. ;

Vizoso, H. ;

Reda, H. ;

Press, S. ;

Kelly, M. E. ;

Rowbotham, M. C. ;

Petersen, K. L. .

NEUROLOGY, 2007, 68 (07) :515-521

[3] Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors [J].

Agarwal, Nitin ;

Pacher, Pal ;

Tegeder, Irmgard ;

Amaya, Fumimasa ;

Constantin, Cristina E. ;

Brenner, Gary J. ;

Rubino, Tiziana ;

Michalski, Christoph W. ;

Marsicano, Giovanni ;

Monory, Krisztina ;

Mackie, Ken ;

Marian, Claudiu ;

Batkai, Sandor ;

Parolaro, Daniela ;

Fischer, Michael J. ;

Reeh, Peter ;

Kunos, George ;

Kress, Michaela ;

Lutz, Beat ;

Woolf, Clifford J. ;

Kuner, Rohini .

NATURE NEUROSCIENCE, 2007, 10 (07) :870-879

[4]

Aggarwal Sunil K, 2009, J Opioid Manag, V5, P257

[5]

Aggarwal Sunil K, 2007, MedGenMed, V9, P52

[6]

Aggarwal Sunil K, 2009, J Opioid Manag, V5, P153

[7]

Amtmann Dagmar, 2004, Am J Hosp Palliat Care, V21, P95, DOI 10.1177/104990910402100206

[8]

[Anonymous], 2010, CAN MED ASSOC J, DOI DOI 10.1503/cmaj.091414

[9]

[Anonymous], 1999, FED REG, V64, P35928

[10] Cannabis, motivation, and life satisfaction in an internet sample [J].

Barnwell, Sara Smucker ;

Earleywine, Mitch ;

Wilcox, Rand .

SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2006, 1 (1)

← 1 2 3 4 5 6 7 8 9 10 →